| Q40131084 | A Human Biofilm-Disrupting Monoclonal Antibody Potentiates Antibiotic Efficacy in Rodent Models of both Staphylococcus aureus and Acinetobacter baumannii Infections |
| Q36554698 | Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis |
| Q35944927 | Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness |
| Q40459002 | Beta-Lactam Antibiotics: Is Continuous Infusion The Preferred Method of Administration? |
| Q50128924 | Changes in outer membrane protein profiles of bacteria after meropenem-induced postantibiotic effect studied by capillary electrophoresis |
| Q33695042 | Characteristics and dynamics of bacterial populations during postantibiotic effect determined by flow cytometry. |
| Q68047623 | Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD) |
| Q35123667 | Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa. |
| Q35656806 | Continuous infusion of beta-lactam antibiotics |
| Q36754206 | Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model |
| Q24803578 | Dynamics of success and failure in phage and antibiotic therapy in experimental infections |
| Q57238214 | Gentamicin volume of distribution in critically ill septic patients |
| Q39779656 | In vitro and in vivo antibacterial activities of BO-2727, a new carbapenem |
| Q34783696 | Integrated pharmacokinetics/pharmacodynamics parameters-based dosing guidelines of enrofloxacin in grass carp Ctenopharyngodon idella to minimize selection of drug resistance |
| Q36754960 | Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model |
| Q33797936 | Pharmacodynamics of cefquinome in a neutropenic mouse thigh model of Staphylococcus aureus infection |
| Q54689513 | Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC. |
| Q33690065 | Postanitbiotic and sub-MIC effects of azithromycin and isepamicin against Staphylococcus aureus and Escherichia coli. |
| Q69199073 | Postantibiotic and bactericidal effect of imipenem against Pseudomonas aeruginosa |
| Q39815200 | Postantibiotic effect of beta-lactam antibiotics on Escherichia coli evaluated by bioluminescence assay of bacterial ATP. |
| Q35354562 | Postantibiotic effects of imipenem, norfloxacin, and amikacin in vitro and in vivo |
| Q33594918 | Postantibiotic leukocyte enhancement of meropenem against gram-positive and gram-negative strains |
| Q72793341 | Review of beta-lactam antibiotics in pregnancy. The need for adjustment of dosage schedules |
| Q35139016 | Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase |
| Q41718334 | The effects of different enrofloxacin dosages on clinical efficacy and resistance development in chickens experimentally infected with Salmonella Typhimurium |
| Q35954896 | Translating slow-binding inhibition kinetics into cellular and in vivo effects |
| Q35132306 | Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem |
| Q35124885 | Variation in postantibiotic effect of clindamycin against clinical isolates of Staphylococcus aureus and implications for dosing of patients with osteomyelitis |